❗Cosibelimab-ipdl (#UNLOXCYT) is now available in the US for advanced #CSCC, delivering ≥50% response rates, durable disease control, and a favorable safety profile. https://t.co/hOr7YfjG8i #DermTwitter #aCSCC

For those that want to follow ACSCC

Today, the FDA approved an updated label for our PD-L1 therapy for people with advanced cutaneous squamous cell carcinoma (aCSCC). With this approval, Sun Pharma will soon introduce this therapy in the US, offering a new treatment option. Read more: https://t.co/ME3aiSJ77D

🚨 Sun Pharma has announced that UNLOXCYT™ (Cosibelimab-ipdl) is now available. This medicine is used for treating advanced cutaneous squamous cell carcinoma (ACSCC), a type of skin cancer.

How often do you ask for a Kelly Clamp in the OR? This is Howard Kelly (1858-1938). Chair of Gynecology ⁦@HopkinsMedicine⁩ ⁦@AmCollSurgeons⁩ #ACSCC

#cc19selfie what a party at the ACSCC

"Anal abscesses aren't life threatening for many of our patients, but they can be a pain in the butt" 😂 Dr. Natalie Kirilcuk starts off Day 2 at #ACSCC with a entertaining and incredibly informative presentation for accessing anal abscesses. #acscc18

And so it begins #ACSCC #COOP #justdoyourbest #cyathere

Sun Pharmaceutical Industries Ltd - FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC) https://t.co/cwmMfSu4yj

🚨Sun Pharmaceutical Industries: 👉FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC) #SunPharma #USFDA #StocksToWatch #stockmarketsindia

At #ACSCC Board of Governors Dinner with two great people. William Schecter,MD and Sam Schecter,MD. Great event

🚀 Sun Pharma’s UNLOXCYT Gains FDA Label Update for Advanced Skin Cancer – Key Insights | MCap 4,29,110.59 Cr - FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma (aCSCC). - First and only PD-L1 immune checkpoint inhibitor

Congratulations Dr. Julie A. Freischlag, MD, FACS, FRCSEd (Hon), DFSVS, on being installed as President of @AmCollSurgeons @JFreischlag #ACSCC! #SurgeonsSewingHope @WomenSurgeons

Thanks to @wernerlogistics & @TRUCKINGdotORG for hosting our @CommerceGov @TradeGov Advisory Committee on Supply Chain Competitiveness (ACSCC) #USMCA #tradejobs

Environmental efficiency: First stop is @Toyota, where #ACSCC gets a demonstration of a hydrogen fuel cell-powered truck. #LASupplyChain

Just in time!💪🏽 #ACSCC2022 #ACSCC @AmCollSurgeons

So grateful for you, @DissanaikeMD & missing you this #ACSCC week! Happy birthday, friend! 😘 🎂 🥂

Sun Pharma’s UNLOXCYT™ Now Available in U.S. for Advanced Skin Cancer Treatment 🩺 | MCap 4,08,009.3 Cr - UNLOXCYT™ (cosibelimab-ipdl) is now available in the U.S. for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (aCSCC) who can’t undergo

In addition to the superlative extensive educational content @AmCollSurgeons #ACSCC the long overdue in-person connection with friends is fabulous @ArgIoannid @TsarkovPetr @pturnermd